Literature DB >> 20572755

Myeloma-associated orbital amyloidosis.

Jeff M Goshe1, Lynn Schoenfield, Todd Emch, Arun D Singh.   

Abstract

Orbital amyloidosis is extremely rare and may be localized finding or secondary to a systematic process. The majority of the patients with orbital amyloidosis have primary localized disease. We report a 55 year old male with multiple myeloma and secondary amyloidosis who presented with incidental bilateral orbital masses on MRI. Biopsy revealed amyloid deposition. We review the previously published cases of the orbital amyloidosis secondary to systematic light chain (AL) amyloidosis, including one patient with multiple myeloma. The clinical signs and symptoms, histopathologic findings, and radiographic features of orbital amyloidosis are discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20572755     DOI: 10.3109/01676831003660671

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  5 in total

1.  Ophthalmic manifestations of atypical IgD multiple myeloma.

Authors:  Matthew R Edmunds; Peter Cikatricis; Subhanjan Mukherji; Jeremy D Bowyer
Journal:  BMJ Case Rep       Date:  2012-07-19

Review 2.  The 2017 Doyne Lecture: the orbit as a window to systemic disease.

Authors:  A A McNab
Journal:  Eye (Lond)       Date:  2017-11-10       Impact factor: 3.775

Review 3.  Ocular adnexal and orbital amyloidosis: a case series and literature review.

Authors:  Eduardo R Mora-Horna; Rubí Rojas-Padilla; Vianhi G López; Martín J Guzmán; Ariel Ceriotto; Guillermo Salcedo
Journal:  Int Ophthalmol       Date:  2015-10-14       Impact factor: 2.031

4.  Clinical presentation, treatment, and prognosis of periocular and orbital amyloidosis in a university-based referral center.

Authors:  Orapan Aryasit; Passorn Preechawai; Kanita Kayasut
Journal:  Clin Ophthalmol       Date:  2013-04-30

5.  Focal Amyloidosis of the Orbit Presenting as a Mass: MRI and CT Features.

Authors:  Hasan Yerli; Erdinc Aydin; Suat Avci; Nihan Haberal; Sibel Oto
Journal:  Iran J Radiol       Date:  2011-12-25       Impact factor: 0.212

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.